Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: A case-control study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Hrbacek, Jan ^a   Urban, Michael ^a,d   Hamsikova, Eva ^b   Tachezy, Ruth ^b   Eis, Vaclav ^a   Brabec, Marek ^c   Heracek, Jiri ^a,d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c INSTITUTE OF COMPUTER SCIENCE   (Czech Republic)

^d Androgeos   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CHLAMYDIA TRACHOMATIS ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; HERPES SIMPLEX VIRUS 1 ANTIBODY; HERPES SIMPLEX VIRUS 2 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 11 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 16 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 18 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 31 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 33 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 6 ANTIBODY; MYCOPLASMA HOMINIS ANTIBODY; NEISSERIA GONORRHOEAE ANTIBODY; TREPONEMA PALLIDUM ANTIBODY; UNCLASSIFIED DRUG; UREAPLASMA UREALYTICUM ANTIBODY; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA HOMINIS; NEISSERIA GONORRHOEAE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; SEROLOGY; SEROPREVALENCE; TREPONEMA PALLIDUM; UREAPLASMA UREALYTICUM; URINARY TRACT INFECTION; ALPHAPAPILLOMAVIRUS; BLOOD; CYTOMEGALOVIRUS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; SIMPLEXVIRUS; SPECIES DIFFERENCE; UROGENITAL TRACT DISEASE; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CHLAMYDIA TRACHOMATIS; COMPLEMENT FIXATION TESTS; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; MYCOPLASMA HOMINIS; NEISSERIA GONORRHOEAE; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; SPECIES SPECIFICITY; TREPONEMA PALLIDUM; UREAPLASMA UREALYTICUM;

EID: 79551517297     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-53     Document Type: Article

References (49)

1. Marberger M. Prostate cancer 2008: Challenges in diagnosis and management. Eur Urol Suppl 2009, 3:89-96.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
3. Herbert JT, Birkhoff JD, Feorino PM, Caldwell GG. Herpes simplex virus type 2 and cancer of the prostate. J Urol 1976, 116:611-612.
4. Baker LH, Mebust WK, Chin TDY, Chapman AL, Hinthorn D, Towle D. The relationship of herpesvirus to carcinoma of the prostate. J Urol 1981, 125:370-374.
5. Strickler HD, Burk R, Shah K, Viscidi R, Jackson A, Pizza G, Bertoni F, Schiller JT, Manns A, Metcalf R, Qu W, Goedert JJ. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998, 82(6):1118-1125. 10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9, 9506358.
6. Hisada M, Rabkin CS, Strickler HD, Wright WE, Christianson RE, van den Berg BJ. Human papillovirus antibody and risk of prostate cancer. JAMA 2000, 3:340-341.
7. Antilla T, Tenkanen L, Lumme S, Leinonen M, Gislefoss RE, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Stattin P, Saikku P, Dillner J, Lehtinen M, Hakama M. Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(2):385-389. 10.1158/1055-9965.EPI-03-0325, 15734962.
8. Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, Thoresen S, Hakulinen T, Stattin P, Luostarinen T, Lehtinen M, Hakama M. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005, 14(12):2952-2955. 10.1158/1055-9965.EPI-05-0602, 16365015.
9. Sitas F, Urban M, Stein L, Beral V, Ruff P, Hale M, Patel M, O'Connell D, Yu XQ, Verzijden A, Marais D, Williamson AL. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infectious Agents and Cancer 2007, 2:6. 10.1186/1750-9378-2-6, 1821007, 17331260.
10. Reiner WG, Walsh PC. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol 1979, 121:198-200.
11. Walsh PC. Anatomic radical prostatectomy. Evolution of the surgical technique. J Urol 1998, 160:2418-2424. 10.1016/S0022-5347(01)62202-X, 9817395.
12. Fuller E. Six successful and successive cases of prostatectomy. J Cutan Genitourin Dis 1895, 13:229-239.
13. Culp DA. Benign prostatic hyperplasia: early recognition and management. Urol Clin North Am 1975, 2:29-48.
14. Montironi R, van der Kwast T, Boccon-Gibod L, Bono AV, Boccon-Gibod L. Handling and patology reporting of radical prostatectomy specimens. Eur Urol 2003, 44:626-636. 10.1016/S0302-2838(03)00381-6, 14644113.
15. Rosai J. Rosai and Ackerman's Surgical Pathology 2004, Edinburgh: Mosby.
16. Eble JN, Kauter G, Epstein JI, Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs (IARC/World Health Organization Classification of Tumours). 2003, Lyon, France: IARC Press.
17. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29(9):1228-1242. 10.1097/01.pas.0000173646.99337.b1, 16096414.
18. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours 2002, Wiley, 6.
19. Srigley JR, Amin MB, Epstein JI, Grignon DJ, Humphrey PH, Renshaw AA, Wheeler TM. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med 2006, 130(7):936-946.
20. Hamsikova E, Smahel M, Sapp M, Munoz N, Bosch FX, Shah KV, Vonka V. Correlation between the presence of anti HPV33 VLP antibodies and HPV DNA in cervical neoplasia patients. Arch Virol 1997, 142(2):413-416. 10.1007/s007050050087, 9125054.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epi 2008, 61:344-349.
22. Kirby RS, Patel MI. Fast facts: Prostate cancer 2009, Oxford: Health Press Limited.
23. Amo FH, Cordero JMD, Tartajo FV, Hernandez FL, Carrillo AB, Burgos JG, Rios DS. Cáncer incidental de próstata. Actas Urol Esp 1999, 23(10):848-852.
24. Dillner J, Knekt P, Boman J, Lehtinen M, Geijersstam VA, Sapp M, Schiller J, Maatela J, Aromaa A. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998, 75:564-567. 10.1002/(SICI)1097-0215(19980209)75:4<564::AID-IJC12>3.0.CO;2-9, 9466657.
25. Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J Inf Dis 2005, 191:2008-2011.
26. Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF, Reding D, Whitby D, Papp JR, Rabkin CS. Sexually Transmissible Infections and Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev 2008, 17(9):2374-2381. 10.1158/1055-9965.EPI-08-0173, 2559953, 18768506.
27. Dennis KL, Coughlin JA, McKinnon BC, Wells TS, Gaydos CA, Hamsikova E, Gray GC. Sexually transmitted infections and prostate cancer among men in the U.S. Military. Cancer Epidemio Biomarkers Prev 2009, 18(10):2665-2671.
28. Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JN, Jacobson LP, De Marzo AM, Willett WC, Platz EA. Serum antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007, 16(8):1573-1580. 10.1158/1055-9965.EPI-07-0134, 3012386, 17684131.
29. Adami HO, Kuper H, Andersson SO, Bergström R, Dillner J. Prostate Cancer Risk and Serologic Evidence of Human Papilloma Virus Infection: A Population-based Case-Control Study. Cancer Epidemiol Biomarkers Prev 2003, 12:872-875.
30. Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, De Marzo AM, Platz EA. Human papillomavirus types 16, 18 and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2010, 19(2):614-618. 10.1158/1055-9965.EPI-09-1080, 2820385, 20142255.
31. Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, Greenberg RS, Schönberg JB, Liff J, Schwartz AG, Hoover RN, Fraumeni JF. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000, 82(3):718-725. 10.1054/bjoc.1999.0986, 2363322, 10682688.
32. Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:763-768.
33. Ravich A, Ravich RA. Prophylaxis of cancer of the prostate, penis, and cervix by circumcision. NY State J Med 1950, 50:1519-1520.
34. Taylor ML, Mainous AG, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005, 37(7):506-512.
35. Stone KM, Karem KL, Sternberg MR, Mc Quillan GM, Poon AD, Unger ER, Reeves WC. Seroprevalence of Human Papillomavirus Type 16 Infection in the United States. J Infect Dis 2002, 186:1396-1402. 10.1086/344354, 12404154.
36. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX. Epidemiology of Human Papillomavirus Infection in Men, Cancers otherthan Cervical and Benign Conditions. Vaccine 2008, 26(Suppl 10):K17-K28. 10.1016/j.vaccine.2008.06.021, 18847554.
37. Jeong WJ, Park SW, Shin M, Lee YJ, Jeon YK, Jung YH, Hah JH, Kwon TK, Song YS, Kim KH, Sung MW. Presence of HPV type 6 in dysplasia and carcinoma arising from recurrent respiratory papillomatosis. Head Neck 2009, 31(8):1095-1101. 10.1002/hed.20998, 19072996.
38. González AB, Urban MI, Sitas F, Blackburn N, Hale M, Patel M, Ruff P, Sur R, Newton R, Beral V. Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: A case control study. Infectious Agents and Cancer 2006, 1:2. 1635002, 17150131., http://www.infectagentscancer.com/content/1/1/2
39. Xu F, Schillinger JA, Sternberg MR, Johnson RE, Lee FK, Nahmias AJ, Markowitz LE. Seroprevalence and Coinfection with Herpes Simplex Virus Type 1 and Type 2 in the United States, 1988- 1994. J Infect Dis 2002, 185:1019-1024. 10.1086/340041, 11930310.
40. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002, 186(Suppl 1):S3-28. 10.1086/343739, 12353183.
41. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003, 170:998-1002. 10.1097/01.ju.0000080263.46164.97, 12913758.
42. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Inf Dis 2006, 43:1143-1151.
43. Wagenlehner FME, Weidner W, Naber KG. Chlamydial infections in urology. World J Urol 2006, 24:4-12. 10.1007/s00345-005-0047-x, 16421732.
44. Stamm WE. Chlamydia trachomatis Infections: Progress and Problems. J Inf Dis 1999, 179(Suppl 2):S380-383.
45. Kramer G, Mitteregger D, Marberger M. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?. Eur Urol 2007, 51:1202-1216. 10.1016/j.eururo.2006.12.011, 17182170.
46. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2004, 26:1170-1181. 10.1093/carcin/bgh317, 15498784.
47. Takeyama K, Mitsuzawa H, Shimizu T, Konishi M, Nishitani C, Sano H, Kunishima Y, Matsukawa M, Takahashi S, Shibata K, Tsukamoto T, Kuroki Y. Prostate cell lines secrete IL-8 in response to Mycoplasma hominis through toll-like receptor 2-mediated mechanism. Prostate 2006, 66:386-391. 10.1002/pros.20358, 16302262.
48. Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS ONE 2009, 4(9):e6872. 10.1371/journal.pone.0006872, 2730529, 19721714.
49. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA. Gonorrhea, Syphilis, Clinical Prostatitis, and the Risk of Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(11):2160-2166. 10.1158/1055-9965.EPI-05-0913, 17119041.